Sarepta Therapeutics’ (SRPT) Sell Rating Reiterated at HC Wainwright

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “sell” rating restated by investment analysts at HC Wainwright in a report released on Thursday,Benzinga reports. They presently have a $75.00 price objective on the biotechnology company’s stock. HC Wainwright’s price objective indicates a potential downside of 31.70% from the stock’s previous close.

SRPT has been the subject of several other reports. Robert W. Baird reduced their price objective on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. Piper Sandler decreased their price objective on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 27th. Deutsche Bank Aktiengesellschaft began coverage on Sarepta Therapeutics in a research report on Tuesday. They set a “hold” rating and a $136.00 price objective on the stock. StockNews.com cut shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Finally, Cantor Fitzgerald raised shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $152.00 to $167.00 in a report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $176.77.

Sarepta Therapeutics Trading Up 0.1 %

Sarepta Therapeutics stock opened at $109.81 on Thursday. Sarepta Therapeutics has a 52-week low of $102.15 and a 52-week high of $173.25. The company has a market cap of $10.49 billion, a P/E ratio of 87.85 and a beta of 0.75. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The business has a 50-day simple moving average of $120.16 and a two-hundred day simple moving average of $125.22.

Insider Activity at Sarepta Therapeutics

In related news, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the transaction, the director now owns 5,880 shares of the company’s stock, valued at approximately $738,234. This trade represents a 21.77 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the sale, the director now directly owns 22,840 shares in the company, valued at $2,851,345.60. The trade was a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by insiders.

Institutional Trading of Sarepta Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of SRPT. Manchester Capital Management LLC increased its position in Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 110 shares during the last quarter. MassMutual Private Wealth & Trust FSB boosted its stake in shares of Sarepta Therapeutics by 169.6% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 156 shares during the period. Sunbelt Securities Inc. grew its holdings in Sarepta Therapeutics by 446.2% during the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 232 shares during the last quarter. Huntington National Bank raised its position in Sarepta Therapeutics by 150.9% in the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 175 shares during the period. Finally, Newbridge Financial Services Group Inc. bought a new stake in Sarepta Therapeutics in the fourth quarter worth about $36,000. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.